Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 2/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | FABP3 | P05413 | 2/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.52 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.52 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.52 |
| ▸ | PRKCA | P17252 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL325125 | 1.00 | DGKA (0.57) | DGKAMGLLFAAHALDH1A1MAPT | |
| Sulfuric Acid SCHEMBL2231605 | 0.97 | DGKA (0.57) | DGKAMGLLFAAHALDH1A1MAPT | |
| Sulfuric Acid SCHEMBL9769254 | 0.97 | DGKA (0.57) | DGKAMGLLFAAHALDH1A1MAPT | |
| Sulfuric Acid SCHEMBL5701170 | 0.97 | DGKA (0.57) | DGKAMGLLFAAHALDH1A1MAPT | |
| Sulfuric Acid SCHEMBL2234318 | 0.94 | DGKA (0.57) | DGKAMGLLFAAHALDH1A1MAPT | |
| Sulfuric Acid SCHEMBL2993713 | 0.91 | DGKA (0.61) | DGKAMGLLFAAHALDH1A1MAPT | |
| SCHEMBL25287675 | 0.91 | DGKA (0.69) | DGKAMGLLFAAHALDH1A1MAPT | |
| SCHEMBL25298871 | 0.91 | DGKA (0.69) | DGKAMGLLFAAHALDH1A1MAPT | |
| SCHEMBL25249563 | 0.91 | DGKA (0.69) | DGKAMGLLFAAHALDH1A1MAPT | |
| SCHEMBL25245502 | 0.91 | DGKA (0.69) | DGKAMGLLFAAHALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796653-A2 | TREATMENT OF PULMONARY HYPERTENSION BY INHALED ILOPROST WITH A MICROPARTICLE FORMULATION | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-20 | — | — | EP | claimed |
| US-20060147520-A1 | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation | COTHERIX, INC. | 2006-07-06 | — | — | US | claimed |
| WO-2006014930-A2 | TREATMENT OF PULMONARY HYPERTENSION BY INHALED ILOPROST WITH A MICROPARTICLE FORMULATION | COTHERIX, INC. (US) | 2006-02-09 | — | — | WO | claimed |
| US-6517860-B1 | Powder of drug and hydrophobically derivatized carbohydrate; efficacy | QUADRANT HOLDINGS CAMBRIDGE, LTD. (GB) | 2003-02-11 | — | — | US | claimed |
| US-20090004269-A1 | Pharmaceutical Composition Comprising a Proton Pump Inhibitor and a Protein Component | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2009-01-01 | — | — | US | disclosed |
| EP-1796653-A2 | TREATMENT OF PULMONARY HYPERTENSION BY INHALED ILOPROST WITH A MICROPARTICLE FORMULATION | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20060147520-A1 | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation | COTHERIX, INC. | 2006-07-06 | — | — | US | disclosed |
| WO-2006014930-A2 | TREATMENT OF PULMONARY HYPERTENSION BY INHALED ILOPROST WITH A MICROPARTICLE FORMULATION | COTHERIX, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060147520-A1 | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation | PTGIR, PTGIS, PTGER1 | DGKA 1328/4885MGLL 1241/4885FAAH 1862/4885 |
| US-20090004269-A1 | Pharmaceutical Composition Comprising a Proton Pump Inhibitor and a Protein Component | ATP6AP1, ATP6V1G1, ATP6V1E1 | DGKA 3334/4885MGLL 1473/4885FAAH 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.